Nicox and Kowa inks up for USD 210.65 million for Glaucoma Treatment NCX 470 in U.S.
Nicox SA, an international ophthalmology company, today announced the signing of a major new agreement concerning NCX 470 with Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-breaking research, development and marketing.